DNAJB4 and breast carcinoma: A 2017 study by Acun et al. showed that DNAJB4 expression levels were reduced in breast cancer cells and correlated with poor prognosis, suggesting that incorporating DNAJB4 expression as a supplementary marker in the TNM classification system could enhance its accuracy, particularly in assessing metastatic risk and patient prognosis [20].